CY1114507T1 - Συγχωνευμενη αμινο πυριδινη ως hsp90 αναστολεας - Google Patents
Συγχωνευμενη αμινο πυριδινη ως hsp90 αναστολεαςInfo
- Publication number
- CY1114507T1 CY1114507T1 CY20131100916T CY131100916T CY1114507T1 CY 1114507 T1 CY1114507 T1 CY 1114507T1 CY 20131100916 T CY20131100916 T CY 20131100916T CY 131100916 T CY131100916 T CY 131100916T CY 1114507 T1 CY1114507 T1 CY 1114507T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hsp90
- suspension
- amino pyridine
- connected amino
- hsp90 inhibitors
- Prior art date
Links
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 title abstract 2
- 101710113864 Heat shock protein 90 Proteins 0.000 title abstract 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89592107P | 2007-03-20 | 2007-03-20 | |
| US1528807P | 2007-12-20 | 2007-12-20 | |
| EP08743755.4A EP2069324B1 (en) | 2007-03-20 | 2008-03-10 | Fused amino pyridine as hsp90 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114507T1 true CY1114507T1 (el) | 2016-10-05 |
Family
ID=39766345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100916T CY1114507T1 (el) | 2007-03-20 | 2013-10-17 | Συγχωνευμενη αμινο πυριδινη ως hsp90 αναστολεας |
Country Status (24)
| Country | Link |
|---|---|
| US (10) | US8324240B2 (enExample) |
| EP (1) | EP2069324B1 (enExample) |
| JP (1) | JP5401329B2 (enExample) |
| KR (1) | KR101313804B1 (enExample) |
| CN (1) | CN101679347B (enExample) |
| AU (1) | AU2008229216B2 (enExample) |
| BR (1) | BRPI0808301B1 (enExample) |
| CA (1) | CA2680778C (enExample) |
| CY (1) | CY1114507T1 (enExample) |
| DK (1) | DK2069324T3 (enExample) |
| EA (1) | EA019103B1 (enExample) |
| ES (1) | ES2430217T3 (enExample) |
| HR (1) | HRP20130910T1 (enExample) |
| IL (2) | IL200924A (enExample) |
| MX (1) | MX2009009936A (enExample) |
| MY (1) | MY148860A (enExample) |
| NZ (1) | NZ579635A (enExample) |
| PL (1) | PL2069324T3 (enExample) |
| PT (1) | PT2069324E (enExample) |
| RS (1) | RS52978B (enExample) |
| SI (1) | SI2069324T1 (enExample) |
| TW (1) | TWI471131B (enExample) |
| WO (1) | WO2008115719A1 (enExample) |
| ZA (1) | ZA200906371B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
| WO2006084030A2 (en) * | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| JP5599610B2 (ja) * | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| SG174772A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| EA019103B1 (ru) * | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| EP2088500A1 (en) | 2008-02-11 | 2009-08-12 | Idean Enterprises Oy | Layer based user interface |
| US8017780B1 (en) | 2008-10-09 | 2011-09-13 | Myrexis, Inc. | Therapeutic compounds and uses thereof |
| CA2786715C (en) * | 2009-01-16 | 2019-05-21 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| TWI460177B (zh) * | 2009-07-10 | 2014-11-11 | Taiho Pharmaceutical Co Ltd | An azabicyclo compound or a salt thereof |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| AU2013204109B2 (en) * | 2009-10-07 | 2016-05-05 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| BR112012008019A2 (pt) * | 2009-10-07 | 2016-03-01 | Sloan Kettering Inst Cancer | derivados de purina úteis como inibidores de hsp90 |
| CA2791994A1 (en) * | 2010-03-05 | 2011-09-09 | Baylor Research Institute | Involvement of androgen/androgen receptor pathway in fabry disease |
| WO2012131413A1 (en) * | 2011-03-25 | 2012-10-04 | Debiopharm Sa | Crystalline forms of fused amino pyridines as hsp90 inhibitors |
| EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| CA2832099C (en) | 2011-04-05 | 2019-07-09 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| JP6289362B2 (ja) * | 2011-04-26 | 2018-03-07 | アールディーディー ファーマ リミテッド | 肛門直腸疾患の処置のためのオキシメタゾリン |
| BR112014019704B1 (pt) | 2012-02-09 | 2022-05-31 | University Of Kansas | Compostos inibidores de hsp90 c-terminais, composição farmacêutica compreendendo os ditos compostos e uso dos mesmos para o tratamento ou prevenção de um distúrbio neurodegenerativo |
| KR20150010793A (ko) | 2012-05-25 | 2015-01-28 | 버그 엘엘씨 | 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들 |
| CA2905509A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Hsp90-targeted cardiac imaging and therapy |
| TW201533043A (zh) | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| CA2921571C (en) * | 2013-08-16 | 2022-04-05 | Memorial Sloan-Kettering Cancer Center | Selective grp94 inhibitors and uses thereof |
| EP3086792B1 (en) | 2013-12-23 | 2022-10-12 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| MX388515B (es) | 2014-06-24 | 2025-03-20 | Univ Kansas | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70. |
| CN107110869B (zh) | 2014-09-17 | 2021-08-10 | 纪念斯隆-凯特琳癌症中心 | Hsp90-靶向炎症和感染成像及治疗 |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| ES2899906T3 (es) | 2015-07-06 | 2022-03-15 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| ES2875562T3 (es) | 2017-01-11 | 2021-11-10 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| DK3448859T3 (da) | 2017-03-20 | 2019-09-23 | Forma Therapeutics Inc | Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer |
| WO2018178767A1 (en) | 2017-03-31 | 2018-10-04 | Alma Bio Therapeutics | Methods of treatment of hla-b27 related inflammatory diseases and compositions related to same |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| EP3794009A1 (en) | 2018-05-14 | 2021-03-24 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| WO2020160151A1 (en) | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
| MX2022003254A (es) | 2019-09-19 | 2022-04-18 | Forma Therapeutics Inc | Composiciones activadoras de piruvato cinasa r (pkr). |
| GB202006382D0 (en) | 2020-04-30 | 2020-06-17 | Spermatech As | Use |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023006993A1 (en) | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
| KR20250083233A (ko) * | 2022-10-06 | 2025-06-09 | 레그라니언, 엘엘씨 | 화농성 한선염 치료를 위한 방법 및 조성물 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025014551A1 (en) * | 2023-07-10 | 2025-01-16 | Regranion, Llc | Methods and compositions for treating atopic dermatitis |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080629A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating behçet's disease |
| WO2025080645A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating bullous pemphigoid |
| WO2025080623A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating discoid lupus erythematosus, systemic lupus erythematosus, and subacute cutaneous lupus erythematosus |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217284A1 (en) * | 2024-04-09 | 2025-10-16 | Regranion, Llc | Methods and compositions for treating inflammatory and autoimmune disorders of the skin |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2167042A1 (en) | 1993-07-15 | 1995-01-26 | Kyle J. Lindstrom | Imidazo[4,5-c]pyridin-4-amines |
| US5644063A (en) * | 1994-09-08 | 1997-07-01 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-c]pyridin-4-amine intermediates |
| US6723727B1 (en) * | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| HUP0101810A3 (en) * | 1998-01-27 | 2002-05-28 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them |
| EP1058549A4 (en) * | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| CA2376835C (en) * | 1999-07-02 | 2009-09-15 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| HUP0203375A3 (en) * | 1999-07-28 | 2005-03-29 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl compounds |
| US20020045613A1 (en) * | 2000-04-27 | 2002-04-18 | Heinz Pauls | 1-aroyl-piperidinyl benzamidines |
| US7439359B2 (en) * | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| ITRM20010465A1 (it) | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| WO2003037860A2 (en) | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| US7160885B2 (en) * | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| CA2518318A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2530081A1 (en) * | 2003-07-01 | 2005-01-13 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| EA010160B1 (ru) * | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| US7547693B2 (en) | 2003-09-22 | 2009-06-16 | Banyu Pharmaceutical Co. Ltd. | Piperidine derivative |
| WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| US20070259881A1 (en) * | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| CA2578975A1 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
| GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| WO2006084030A2 (en) * | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| CA2605738C (en) * | 2005-04-25 | 2013-10-01 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Novel azaheterocyclic compounds as kinase inhibitors |
| WO2007035963A2 (en) * | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
| EP1962863A4 (en) * | 2005-12-22 | 2010-11-24 | Conforma Therapeutics Corp | ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90 |
| WO2007092496A2 (en) * | 2006-02-07 | 2007-08-16 | Conforma Therapeutics Corporation | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors |
| AU2007216247A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as TLR7 modulators |
| JP2009536960A (ja) * | 2006-05-12 | 2009-10-22 | ミリアド ジェネティクス， インコーポレイテッド | 治療用化合物および癌におけるそれらの使用 |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| SG174772A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| CA2667826C (en) | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EA019103B1 (ru) * | 2007-03-20 | 2014-01-30 | Кьюрис, Инк. | Конденсированный аминопиридин в качестве ингибиторов hsp90 |
| US20080234297A1 (en) * | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| CA2786715C (en) | 2009-01-16 | 2019-05-21 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
-
2008
- 2008-03-10 EA EA200901263A patent/EA019103B1/ru unknown
- 2008-03-10 ES ES08743755T patent/ES2430217T3/es active Active
- 2008-03-10 CN CN200880016525.7A patent/CN101679347B/zh active Active
- 2008-03-10 US US12/045,509 patent/US8324240B2/en active Active
- 2008-03-10 KR KR1020097021910A patent/KR101313804B1/ko active Active
- 2008-03-10 MX MX2009009936A patent/MX2009009936A/es active IP Right Grant
- 2008-03-10 CA CA2680778A patent/CA2680778C/en active Active
- 2008-03-10 PL PL08743755T patent/PL2069324T3/pl unknown
- 2008-03-10 RS RS20130434A patent/RS52978B/sr unknown
- 2008-03-10 MY MYPI20093837A patent/MY148860A/en unknown
- 2008-03-10 WO PCT/US2008/056396 patent/WO2008115719A1/en not_active Ceased
- 2008-03-10 SI SI200831049T patent/SI2069324T1/sl unknown
- 2008-03-10 EP EP08743755.4A patent/EP2069324B1/en active Active
- 2008-03-10 JP JP2009554633A patent/JP5401329B2/ja active Active
- 2008-03-10 AU AU2008229216A patent/AU2008229216B2/en active Active
- 2008-03-10 HR HRP20130910AT patent/HRP20130910T1/hr unknown
- 2008-03-10 PT PT87437554T patent/PT2069324E/pt unknown
- 2008-03-10 NZ NZ579635A patent/NZ579635A/en unknown
- 2008-03-10 DK DK08743755.4T patent/DK2069324T3/da active
- 2008-03-10 BR BRPI0808301-0A patent/BRPI0808301B1/pt active IP Right Grant
- 2008-03-13 TW TW97108801A patent/TWI471131B/zh active
-
2009
- 2009-09-14 IL IL200924A patent/IL200924A/en active IP Right Grant
- 2009-09-14 ZA ZA200906371A patent/ZA200906371B/xx unknown
-
2012
- 2012-03-20 US US13/424,780 patent/US8586605B2/en active Active
-
2013
- 2013-10-15 US US14/054,273 patent/US9040556B2/en active Active
- 2013-10-17 CY CY20131100916T patent/CY1114507T1/el unknown
-
2015
- 2015-01-26 IL IL236938A patent/IL236938A0/en unknown
- 2015-04-08 US US14/681,310 patent/US9402832B2/en active Active
-
2016
- 2016-07-01 US US15/200,232 patent/US9630965B2/en active Active
-
2017
- 2017-03-30 US US15/474,248 patent/US10035797B2/en active Active
-
2018
- 2018-07-11 US US16/032,282 patent/US10428068B2/en active Active
-
2019
- 2019-08-28 US US16/553,764 patent/US10844056B2/en active Active
-
2020
- 2020-10-29 US US17/083,964 patent/US11560377B2/en active Active
-
2022
- 2022-12-15 US US18/081,966 patent/US20230192687A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114507T1 (el) | Συγχωνευμενη αμινο πυριδινη ως hsp90 αναστολεας | |
| CY1113798T1 (el) | Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης | |
| CY1120517T1 (el) | Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια | |
| CY1120267T1 (el) | Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας | |
| CY1120144T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| CY1119901T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
| CY1122646T1 (el) | Δικυκλικες ετεροαρυλ ενωσεις | |
| CY1115316T1 (el) | Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων | |
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| CY1120556T1 (el) | Δικυκλικα ετεροκυκλα ως αναστολεις fgfr | |
| CY1121327T1 (el) | Τροποποιημενα αντισωματα anti-il-23p19 | |
| CY1115236T1 (el) | Ενωσεις για την προληψη και τη θεραπεια των καρδιαγγειακων παθησεων | |
| CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
| CY1119476T1 (el) | Αναστολεις της απομεθυλασης ιστονης | |
| CY1119454T1 (el) | Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος | |
| CY1116842T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
| CY1116886T1 (el) | C-met αντισωματα | |
| CY1114277T1 (el) | ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ | |
| CY1115357T1 (el) | Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων νοσηματων | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| CY1121046T1 (el) | Στοχευση toy abcb5 για θεραπεια του καρκινου | |
| CY1113924T1 (el) | Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων | |
| CY1105078T1 (el) | Ανταγωνιστες τεκ | |
| MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
| MA32349B1 (fr) | Antagonistes de la voie hedgehog a base de phtalazines disubstituees |